StarWise

Starwise is a clinical-stage biotechnology company headquartered in Beijing, China, dedicated to the discovery and development of small interfering RNA (siRNA) therapeutics. The company utilizes its proprietary RNAi technology platforms, including advanced GalNAc conjugation and delivery systems, to target liver-expressed genes involved in chronic diseases. Its lead programs focus on treating chronic hepatitis B virus (HBV) infection and metabolic conditions such as hyperlipidemia. Starwise is backed by prominent life science investors and aims to deliver highly potent and long-acting genetic medicines. The company's approach emphasizes precision targeting and improved safety profiles compared to traditional modalities. By leveraging deep expertise in nucleic acid chemistry, Starwise is positioning itself as a leader in the next generation of RNA-based treatments in Asia.